Brigatinib in <i>NF2</i> -Related Schwannomatosis with Progressive Tumors

Abstract

Brigatinib treatment resulted in radiographic responses in multiple tumor types and clinical benefit in a heavily pretreated cohort of patients with <i>NF2</i>-SWN. (Funded by the Children's Tumor Foundation and others; INTUITT-NF2 ClinicalTrials.gov number, NCT04374305.).